Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

Author： Rosenberg Per   Andersson Ha˚kan   Boman Karin   Ridderheim Mona   Sorbe Bengt   Puistola Ulla   Parö Gunnar  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.41, Iss.5, 2002-09, pp. : 418-424

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

By Koizumi Tomonobu   Yoshiike Fumiaki   Inou Hitoshi   Hatayama Orie   Sasabayashi Mari   Tsushima Kenji   Yamamoto Hiroshi   Hayasaka Muneharu   Kubo Keishi  

Medical Oncology, Vol. 21, Iss. 2, 2004-06 ,pp. : 133-138

Humana Press, Inc

Access to resources Recommend Favorite

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum

By du Bois A.   Luck H.J.   Buser K.   Meerpohl H.G.   Sessa C.   Klaassen U.   Meden H.   Bochtler H.   Diergarten K.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 379-384

Elsevier

Access to resources Recommend Favorite

Phase 2 Trial of Moderately High Dose Single Agent Mitoxantrone in Platinum and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Lichtman S.M.   Homesley H.   Kennedy A.   Webster K.   Ernst S.   Omura G.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 1, 1998-07 ,pp. : 123-126

Elsevier

Access to resources Recommend Favorite